NRIX - Nurix Therapeutics, Inc.
17.08
0.590 3.454%
Share volume: 1,116,174
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations:
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$16.49
0.59
0.04%
View ratios
| Fiscal Date | 05-31-2024 | 08-31-2024 | 11-30-2024 | 02-28-2025 | 05-31-2025 | 08-31-2025 | 11-30-2025 | 02-28-2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
| Report Date | 07-11-2024 | 10-11-2024 | 01-28-2025 | 04-08-2025 | 07-09-2025 | 10-09-2025 | 01-28-2026 | 04-08-2026 | |
| Assets | |||||||||
| Total Assets | 511.031 M | 513.600 M | 669.343 M | 615.043 M | 591.555 M | 522.472 M | 688.135 M | 636.130 M | |
| Current Assets | 450.217 M | 456.043 M | 619.387 M | 563.703 M | 515.330 M | 440.603 M | 606.819 M | 554.394 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 7.078 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 7.078 M | 349.008 M | 499.586 M | 473.764 M | 401.521 M | 350.391 M | 345.981 M | 469.537 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 443.139 M | 99.044 M | 109.997 M | 75.916 M | 84.260 M | 78.438 M | 246.960 M | 71.195 M | |
| Total Non-current Assets | 60.814 M | 9.472 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 18.557 M | 17.069 M | 17.757 M | 18.449 M | 18.773 M | 20.498 M | 22.490 M | 21.697 M | |
| Other Assets | 31.976 M | 40.488 M | 32.199 M | 32.891 M | 57.452 M | 61.371 M | 58.826 M | 60.039 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 511.031 M | 513.600 M | 669.343 M | 615.043 M | 591.555 M | 522.472 M | 688.135 M | 636.130 M | |
| Total liabilities | 140.338 M | 136.744 M | 142.350 M | 134.126 M | 143.952 M | 150.220 M | 149.388 M | 155.237 M | |
| Total current liabilities | 80.779 M | 86.296 M | 95.854 M | 89.988 M | 75.614 M | 82.350 M | 86.471 M | 92.199 M | |
| Accounts Payable | 2.813 M | 3.918 M | 11.482 M | 8.397 M | 5.954 M | 8.609 M | 11.215 M | 10.293 M | |
| Other liabilities | 38.674 M | 20.590 M | 20.289 M | 19.984 M | 46.696 M | 52.695 M | 52.906 M | 55.453 M | |
| Current long term debt | 7.934 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 20.885 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 38.674 M | 20.590 M | 20.289 M | 19.984 M | 46.696 M | 52.695 M | 52.906 M | 55.453 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 370.693 M | 376.856 M | 526.993 M | 480.917 M | 447.603 M | 372.252 M | 538.747 M | 480.893 M | |
| Common stock | 62.378 M | 1.057 B | 1.266 B | 1.276 B | 1.286 B | 1.297 B | 1.542 B | 1.571 B | |
| Retained earnings | -631.264 M | -680.220 M | -738.769 M | -795.120 M | -838.584 M | -925.005 M | -1.003 B | -1.090 B |